{"id":"NCT02513160","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-30","primaryCompletion":"2016-03-31","completion":"2016-03-31","firstPosted":"2015-07-31","resultsPosted":"2017-09-11","lastUpdate":"2021-11-09"},"enrollment":713,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Persistent Asthma"],"interventions":[{"type":"DRUG","name":"Beclomethasone Dipropionate 640","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Beclomethasone dipropionate via 320 mcg BAI","otherNames":[]},{"type":"DRUG","name":"albuterol/salbutamol","otherNames":["ProAir®"]},{"type":"DRUG","name":"Beclomethasone dipropionate via 320 mcg MDI","otherNames":["QVAR® Inhalation Aerosol"]}],"arms":[{"label":"Beclomethasone dipropionate BAI 320","type":"EXPERIMENTAL"},{"label":"Beclomethasone dipropionate BAI 640","type":"EXPERIMENTAL"},{"label":"Beclomethasone dipropionate MDI 320","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo treatment in patients with persistent asthma as assessed by the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) forced expiratory volume in 1 second (FEV1) area under the effect curve from time 0 to 6 weeks (AUEC\\[0-6wk\\]).","primaryOutcome":{"measure":"Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 6 Weeks (AUEC(0-6wk))","timeFrame":"Baseline (Day 0 of Treatment Period), weeks 2, 4, 6","effectByArm":[{"arm":"Placebo","deltaMin":62,"sd":23},{"arm":"BAI 320 mcg/Day","deltaMin":205,"sd":23.2},{"arm":"BAI 640 mcg/Day","deltaMin":212,"sd":23.3},{"arm":"MDI 320 mcg/Day","deltaMin":210,"sd":23}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":17},"locations":{"siteCount":75,"countries":["United States"]},"refs":{"pmids":["31047115","29317015"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":713},"commonTop":["Upper respiratory tract infection"]}}